Multimodal Imaging Outcome Measures for ALS (Image ALS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

March 17, 2022

Study Completion Date

March 17, 2022

Conditions
ALS
Interventions
DRUG

[11C]-PBR28

"A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner."

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biogen

INDUSTRY

collaborator

University of Miami

OTHER

collaborator

University of Kansas

OTHER

lead

University of Pennsylvania

OTHER